Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

21.57 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,549
Open 21.57
Bid (Size) 21.50 (4)
Ask (Size) 21.59 (1)
Prev. Close 21.57
Today's Range 21.57 - 21.57
52wk Range 1.640 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks. 
Via The Motley Fool

Performance

YTD
+717.05%
+717.05%
1 Month
-17.73%
-17.73%
3 Month
+121.23%
+121.23%
6 Month
+514.53%
+514.53%
1 Year
+1041.27%
+1041.27%

More News

Read More
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
Via The Motley Fool
(SMMT) - Analyzing Summit Therapeutics's Short Interest
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Via Benzinga
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Could Summit Therapeutics Become the Next Merck?
Via The Motley Fool
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
From Summit Therapeutics Inc.
Via Business Wire
Where Will Summit Therapeutics Be in 3 Years?
Via The Motley Fool
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Via Benzinga
Has Summit Therapeutics Stock Already Peaked?
Via The Motley Fool
Is Summit Therapeutics Stock a Buy?
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Via Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Via The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.